All News

2020

March

Featured News / Mar 27, 2020

Novartis announces further steps to protect and support its associates during the COVID-19 Pandemic

Read More
Molecular glues bring proteins together
Story / Mar 27, 2020

Visualizing molecular glues

Molecular glues are a new type of medicine inspired by nature’s matchmakers.

Read More
A heart failure carer discusses their experiences
Story / Mar 26, 2020

Caring for someone with heart failure

Caring for someone with heart failure can be both demanding and rewarding. Learn about the impact of being a carer and the support that carers need.

Read More
Media Release / Mar 26, 2020

Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

Read More
Media Release / Mar 24, 2020

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

Read More
Media Release / Mar 24, 2020

AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2

Read More
Media Release / Mar 20, 2020

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Read More
Media Release / Mar 19, 2020

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)

Read More
Media Release / Mar 18, 2020

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Read More
Media Release / Mar 17, 2020

Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More